Shares of Indivior PLC (LON:INDV) have earned a consensus rating of “Buy” from the seven brokerages that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is GBX 419.29 ($5.34).
A number of research analysts have weighed in on the company. Deutsche Bank AG reiterated a “buy” rating and set a GBX 395 ($5.03) target price on shares of Indivior PLC in a report on Thursday, February 23rd. Numis Securities Ltd reiterated a “buy” rating and set a GBX 490 ($6.24) target price on shares of Indivior PLC in a report on Wednesday, May 31st. Stifel Nicolaus reissued a “buy” rating and issued a GBX 500 ($6.37) price target on shares of Indivior PLC in a research report on Tuesday, April 4th. Royal Bank Of Canada cut Indivior PLC to a “sector performer” rating and boosted their price target for the stock from GBX 370 ($4.71) to GBX 390 ($4.97) in a research report on Monday, March 13th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a GBX 490 ($6.24) price target on shares of Indivior PLC in a research report on Wednesday, June 7th.
Indivior PLC (LON INDV) traded up 1.42% during trading on Tuesday, reaching GBX 321.30. The company had a trading volume of 1,095,499 shares. The company’s market capitalization is GBX 2.32 billion. The company has a 50 day moving average price of GBX 325.28 and a 200 day moving average price of GBX 320.88. Indivior PLC has a 52-week low of GBX 202.81 and a 52-week high of GBX 382.30.
Indivior PLC Company Profile
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.